Long-term safety of pirtobrutinib in people with chronic lymphocytic leukemia
Studies long-term safety of pirtobrutinib in adults with previously treated leukemia or lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Key facts
- Where
- Zagreb, CroatiaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people already taking part in study LOXO-BTK-20020 (J2N-MC-JZNN). It follows the long-term safety of pirtobrutinib in previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Earlier treatment
- Must be actively taking part in study J2N-MC-JZNN/LOXO-BTK-20020.
Read by machine on 9 November 2026.
Where in Croatia
- University Hospital Center ZagrebZagreb, CroatiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07218341
- Record updated
- 4 November 2026
- Original description
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.Read full original descriptionShow less
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Inclusion: Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020.
Exclusion: This is not applicable to this study.